Transcriptome Profiling and Endometrial Receptivity
Transcriptome Profiling and Immune/ Biochemical Markers of Peripheral Blood to Predict Endometrial Receptivity and Successful Implantation
1 other identifier
observational
220
1 country
1
Brief Summary
The aim of this study is to correlate and identify the biochemical markers which may reflect WOI. Blood samples will be collected and endometrial biopsy will be performed at particular time points.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2015
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 20, 2015
CompletedFirst Submitted
Initial submission to the registry
April 3, 2019
CompletedFirst Posted
Study publicly available on registry
April 24, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedMarch 27, 2025
March 1, 2025
10.7 years
April 3, 2019
March 26, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
The change of the transcriptome profiling in the peripheral blood
RNA per sample will be prepared into two portions. One is for RNA sequencing and the other is for small RNA sequencing. The next step is hydrolysis of RNA into 200-300 nucleotides prior to reverse transcription. When sequencing RNA other than mRNA the library preparation is modified. The cellular RNA is selected based on the desired size range. For miRNA, the RNA is isolated through size selection. Once isolated, linkers are added to the 3' and 5' end then purified. The final step is cDNA generation through reverse transcription.
From the day of endometrial biopsy through study completion, an average of 2 months
The change of the immune markers in the peripheral blood
Immune markers including cytokines such as leukemia inhibitory factor, macrophage colony stimulating factor, interleukin - 1 beta, transforming growth factor beta-1, Tim-3, galectin-9 and other markers considered to play a role in implantation will also be measured.
From the day of endometrial biopsy through study completion, an average of 2 months
Interventions
patient will be performed endometrial biopsy and collected blood samples at particular time points
Eligibility Criteria
Subjects will be recruited from the Prince of Wales Hospital.
You may qualify if:
- Age 20-40 years.
You may not qualify if:
- Uncorrected uterine anomalies, such as septate or bicornuate uterus, fibroids (submucous/intramural).
- Intrauterine adhesions.
- Adenomyosis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Chinese University of Hong Kong
Hong Kong, Hong Kong
Biospecimen
blood samples
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Pui Wah Jacqueline Chung, MBBS
Chinese University of Hong Kong
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
April 3, 2019
First Posted
April 24, 2019
Study Start
April 20, 2015
Primary Completion
December 31, 2025
Study Completion
December 31, 2025
Last Updated
March 27, 2025
Record last verified: 2025-03